<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369677</url>
  </required_header>
  <id_info>
    <org_study_id>2020H0066</org_study_id>
    <nct_id>NCT04369677</nct_id>
  </id_info>
  <brief_title>Thermoregulation Among Individuals With First-episode Psychosis</brief_title>
  <official_title>Thermoregulation Among Individuals With First-episode Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholas Breitborde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project will evaluate thermoregulatory processes among individuals with and without
      first-episode psychosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project will evaluate thermoregulatory processes among individuals with and without
      first-episode psychosis.

      Aim 1: Assess whether individuals with first-episode psychosis have differences in mean
      temperature and diurnal temperature variation as compared to individuals without psychosis.

      Aim 2: Examine whether mean temperature and temperature variation during periods of rest and
      activity are different between individuals with first-episode psychosis versus people without
      psychosis.

      Aim 3: Explore the association between current core body temperature and current ratings of
      psychotic symptomatology among individuals with first-episode psychosis.

      Study participants will complete baseline assessments (e.g., symptoms, functioning, and
      sleep) and then complete a 24-36 hour ambulatory assessment period in which core temperature,
      activity, sleep, and heart rate variability will be tracked continuously and symptom severity
      will be assessed sporadically using a symptom rating app on their smart phone. .Then they
      will complete a second study visit to repeat baseline assessments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">April 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in mean temperature and diurnal temperature variation</measure>
    <time_frame>24 hour intervals</time_frame>
    <description>Differences in mean temperature and diurnal temperature variation in individuals with first-episode psychosis as compared to individuals without psychosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in mean temperature and temperature variation during periods of rest and activity</measure>
    <time_frame>24 hour intervals</time_frame>
    <description>Differences in mean temperature and temperature variation during periods of rest and activity between individuals with first-episode psychosis versus people without psychosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association of core body temperature and ratings of psychotic symptomatology in FEP</measure>
    <time_frame>24 hour intervals</time_frame>
    <description>Association between core body temperature and ratings of psychotic symptomatology among individuals with first-episode psychosis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psychosis</condition>
  <condition>First Episode Psychosis</condition>
  <arm_group>
    <arm_group_label>First-Episode Psychosis</arm_group_label>
    <description>Twenty individuals with FEP will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Twenty age-matched individuals with no psychotic disorder will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Eligibility for Individuals with First-Episode Psychosis:

          1. Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic
             features as determined using the Structured Clinical Interview for the DSM-5 .

          2. Less than 5 years since the onset of frank psychotic symptoms as determined using the
             Symptom Onset in Schizophrenia Inventory.

          3. No evidence of a pre-existing intellectual disability defined as a premorbid IQ &gt;70 as
             estimated using the Reading subtest of the Wide Range Achievement Test-4.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility for Individuals with First-Episode Psychosis:

          1. Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic
             features as determined using the Structured Clinical Interview for the DSM-5 .

          2. Less than 5 years since the onset of frank psychotic symptoms as determined using the
             Symptom Onset in Schizophrenia Inventory.

          3. No evidence of a pre-existing intellectual disability defined as a premorbid IQ &gt;70 as
             estimated using the Reading subtest of the Wide Range Achievement Test-4.

        Eligibility for Individuals without First-Episode Psychosis:

          1. No diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic
             features as determined using the Structured Clinical Interview for the DSM-5.

          2. No evidence of a pre-existing intellectual disability defined as a premorbid IQ &gt;70 as
             estimated using the Reading subtest of the Wide Range Achievement Test-4.

        Eligibility for Individuals with and without First-Episode Psychosis:

          1. Ages 18 - 35

          2. No evidence of swallowing difficulties as assessed using the Swallowing Disturbance
             Questionnaire [SDQ]. defined as (i) a score &lt;5 on the SDQ oral phase questions, (ii) a
             score &lt;11.5 on the laryngopharygeal phase SDQ questions, and a total SDQ score &lt; 12.5.

          3. Not meeting diagnostic criteria for a substance use disorder over the past month as
             determined using the Structured Clinical Interview for the DSM-5 .

          4. No current or past diagnosis of a medical condition known to affect thermoregulatory
             Functioning as assessed using the Health Conditions that Affect Thermoregulation
             questionnaire

          5. Per recommendations from the manufacturer of the CorTemp continuous temperature
             sensor, we will not enroll:

               1. Individuals who weigh less than 80 pounds

               2. Individuals diagnosed with known or suspected obstructive diseases of the
                  gastrointestinal tract

               3. Individuals with a history of gag reflex disorders or impairments

               4. Individuals with previous or scheduled gastrointestinal surgery

               5. Individuals having felinization of the esophagus

               6. Individuals with conditions that would result in hypomotility of the GI tract.

               7. Individuals scheduled to undergo Magnetic Resonance Imaging or Nuclear Magnetic
                  Resonance in the next month

               8. Individuals with cardiac pacemaker or other implanted electric medical devices
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicholas Breitborde, PhD</last_name>
    <phone>(614) 685-6052</phone>
    <email>nicholas.breitborde@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harding Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Breitborde, PhD</last_name>
      <phone>614-685-6052</phone>
      <email>nicholas.breitborde@osumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lu BY, Cullen CE, Eide CE, Williams CC, Apfeldorf WJ. Antidepressant-induced sweating alleviated by aripiprazole. J Clin Psychopharmacol. 2008 Dec;28(6):710-1. doi: 10.1097/JCP.0b013e31818d6b67.</citation>
    <PMID>19011447</PMID>
  </reference>
  <reference>
    <citation>Vybíral S, Janský L. The role of dopaminergic pathways in thermoregulation in the rabbit. Neuropharmacology. 1989 Jan;28(1):15-20.</citation>
    <PMID>2927577</PMID>
  </reference>
  <reference>
    <citation>Heh CW, Herrera J, DeMet E, Potkin S, Costa J, Sramek J, Hazlett E, Buchsbaum MS. Neuroleptic-induced hypothermia associated with amelioration of psychosis in schizophrenia. Neuropsychopharmacology. 1988 May;1(2):149-56.</citation>
    <PMID>3251495</PMID>
  </reference>
  <reference>
    <citation>Rubinstein G. Schizophrenia, infection and temperature. An animal model for investigating their interrelationships. Schizophr Res. 1993 Aug;10(2):95-102. Review.</citation>
    <PMID>8398951</PMID>
  </reference>
  <reference>
    <citation>Lkhagvasuren B, Nakamura Y, Oka T, Sudo N, Nakamura K. Social defeat stress induces hyperthermia through activation of thermoregulatory sympathetic premotor neurons in the medullary raphe region. Eur J Neurosci. 2011 Nov;34(9):1442-52. doi: 10.1111/j.1460-9568.2011.07863.x. Epub 2011 Oct 6.</citation>
    <PMID>21978215</PMID>
  </reference>
  <reference>
    <citation>Hayashida S, Oka T, Mera T, Tsuji S. Repeated social defeat stress induces chronic hyperthermia in rats. Physiol Behav. 2010 Aug 4;101(1):124-31. doi: 10.1016/j.physbeh.2010.04.027. Epub 2010 May 10.</citation>
    <PMID>20438740</PMID>
  </reference>
  <reference>
    <citation>Keeney AJ, Hogg S, Marsden CA. Alterations in core body temperature, locomotor activity, and corticosterone following acute and repeated social defeat of male NMRI mice. Physiol Behav. 2001 Sep 1-15;74(1-2):177-84.</citation>
    <PMID>11564466</PMID>
  </reference>
  <reference>
    <citation>Radonjić NV, Petronijević ND, Vucković SM, Prostran MS, Nesić ZI, Todorović VR, Paunović VR. Baseline temperature in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Physiol Behav. 2008 Feb 27;93(3):437-43. Epub 2007 Oct 10.</citation>
    <PMID>17996259</PMID>
  </reference>
  <reference>
    <citation>Horvath G, Kekesi G, Petrovszki Z, Benedek G. Abnormal Motor Activity and Thermoregulation in a Schizophrenia Rat Model for Translational Science. PLoS One. 2015 Dec 2;10(12):e0143751. doi: 10.1371/journal.pone.0143751. eCollection 2015.</citation>
    <PMID>26629908</PMID>
  </reference>
  <reference>
    <citation>Chong TW, Castle DJ. Layer upon layer: thermoregulation in schizophrenia. Schizophr Res. 2004 Aug 1;69(2-3):149-57. Review.</citation>
    <PMID>15469188</PMID>
  </reference>
  <reference>
    <citation>Arnold VK, Rosenthal TL, Dupont RT, Hilliard D. Redundant clothing: a readily observable marker for schizophrenia in the psychiatric emergency room population. J Behav Ther Exp Psychiatry. 1993 Mar;24(1):45-7.</citation>
    <PMID>8370796</PMID>
  </reference>
  <reference>
    <citation>Shiloh R, Schapir L, Bar-Ziv D, Stryjer R, Konas S, Louis R, Hermesh H, Munitz H, Weizman A, Valevski A. Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients. Eur Neuropsychopharmacol. 2009 Sep;19(9):654-8. doi: 10.1016/j.euroneuro.2009.04.010. Epub 2009 Jun 2.</citation>
    <PMID>19493658</PMID>
  </reference>
  <reference>
    <citation>Mazerolle SM, Ganio MS, Casa DJ, Vingren J, Klau J. Is oral temperature an accurate measurement of deep body temperature? A systematic review. J Athl Train. 2011 Sep-Oct;46(5):566-73. Review.</citation>
    <PMID>22488144</PMID>
  </reference>
  <reference>
    <citation>Palmier-Claus JE, Ainsworth J, Machin M, Barrowclough C, Dunn G, Barkus E, Rogers A, Wykes T, Kapur S, Buchan I, Salter E, Lewis SW. The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry. 2012 Oct 17;12:172. doi: 10.1186/1471-244X-12-172.</citation>
    <PMID>23075387</PMID>
  </reference>
  <reference>
    <citation>First, M.B., et al., Structured Clinical Interview for DSM-5-Research Version2015, Arlington, VA: American Psychiatric Association.</citation>
  </reference>
  <reference>
    <citation>Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res. 2000 Jul 7;44(1):1-10.</citation>
    <PMID>10867307</PMID>
  </reference>
  <reference>
    <citation>Wilkinson, G.S. and G.J. Robertson, Wide Range Achievement Test (WRAT4)2006, Lutz, FL: PAR, Inc</citation>
  </reference>
  <reference>
    <citation>Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. Mov Disord. 2007 Oct 15;22(13):1917-21.</citation>
    <PMID>17588237</PMID>
  </reference>
  <reference>
    <citation>Cohen JT, Manor Y. Swallowing disturbance questionnaire for detecting dysphagia. Laryngoscope. 2011 Jul;121(7):1383-7. doi: 10.1002/lary.21839. Epub 2011 Jun 10.</citation>
    <PMID>21671239</PMID>
  </reference>
  <reference>
    <citation>Cheshire WP Jr. Thermoregulatory disorders and illness related to heat and cold stress. Auton Neurosci. 2016 Apr;196:91-104. doi: 10.1016/j.autneu.2016.01.001. Epub 2016 Jan 6. Review.</citation>
    <PMID>26794588</PMID>
  </reference>
  <reference>
    <citation>Auther, A., C. Smith, and B. Cornblatt, Global Functioning: Social Scale (GF: Social). Glen Oaks, NY: Zucker-Hillside Hospital, 2006.</citation>
  </reference>
  <reference>
    <citation>Niendam, T., et al., Global Functioning: Role Scale (GF: Role). Los Angeles, CA: University of California, Los Angeles, 2006.</citation>
  </reference>
  <reference>
    <citation>Hays, R.D., S. Prince-Embury, and H.Y. Chen, RAND-36 Health Status Inventory1998, San Antonio, TX: The Psychological Corporation.</citation>
  </reference>
  <reference>
    <citation>Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213.</citation>
    <PMID>2748771</PMID>
  </reference>
  <reference>
    <citation>Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.</citation>
    <PMID>3616518</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Nicholas Breitborde</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

